Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi XDC Raises $520 Million in IPO; Climbs 39% in First Trading Session

publication date: Nov 17, 2023

WuXi XDC, an ADC/bioconjugate CRDMO, staged a very successful US$520 million IPO in Hong Kong, rising 39% in its first trading session, challenging the notion that the IPO market is hopelessly closed to China biopharmas. It didn’t hurt the IPO that ADCs/bioconjugates are the current center of interest for novel biopharma development globally. Now 10 years old, WuXi XDC started off its life as part of WuXi Biologics, a CRDMO for biologic drug development, which was in turn started by WuXi AppTec, a CRO that made China drug development globally respectable. WuXi XDC has a market capitalization of US$4.2 billion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital